IDH1 Gene

• The IDH1 gene encodes isocitrate dehydrogenase 1, an enzyme essential for cellular metabolism.
• Its primary IDH1 gene function is to convert isocitrate to alpha-ketoglutarate (α-KG).
• Specific IDH1 gene mutations lead to the production of an oncometabolite, 2-hydroxyglutarate (2-HG).
• These mutations are frequently associated with various cancers, including gliomas and acute myeloid leukemia.
• Targeting IDH1 mutations is a focus for developing new cancer therapies.

What is the IDH1 Gene?

The IDH1 gene, short for Isocitrate Dehydrogenase 1, is a gene located on chromosome 2 in humans. It provides instructions for making the enzyme isocitrate dehydrogenase 1. This enzyme is primarily found in the cytoplasm and peroxisomes of cells, where it plays a critical role in cellular metabolism.

The primary IDH1 gene function involves catalyzing the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG). This reaction is a key step in the citric acid cycle, also known as the Krebs cycle, which is central to energy production in cells. Beyond energy metabolism, α-KG serves as a co-factor for numerous enzymes involved in various cellular processes, including epigenetics, collagen synthesis, and neurotransmitter regulation. The proper functioning of the IDH1 enzyme is therefore essential for maintaining cellular homeostasis and regulating diverse biological pathways.

IDH1 Gene Mutations and Their Role in Cancer

A specific IDH1 gene mutation, most commonly affecting arginine at position 132 (R132), leads to a profound change in the enzyme’s activity. Instead of converting isocitrate to α-KG, the mutated IDH1 enzyme gains a new function: it converts α-KG to an oncometabolite called 2-hydroxyglutarate (2-HG). This accumulation of 2-HG is a hallmark of IDH1-mutant cancers.

The presence of 2-HG disrupts normal cellular processes by inhibiting several α-KG-dependent enzymes, including those involved in epigenetic regulation such as histone demethylases and TET methylcytosine dioxygenases. This inhibition leads to widespread changes in gene expression, promoting cell proliferation, inhibiting differentiation, and ultimately contributing to tumor formation and progression. The role of the IDH1 gene cancer connection is particularly significant in certain malignancies.

Research indicates that IDH1 mutations are prevalent in several types of cancer. For instance, approximately 70-80% of grade II and III gliomas and secondary glioblastomas harbor IDH1 mutations. These mutations are also found in a smaller percentage of other cancers, including acute myeloid leukemia (AML) and cholangiocarcinoma. The identification of IDH1 mutations has not only improved diagnostic classification but has also opened new avenues for targeted therapies, with several IDH1 inhibitors now approved or in clinical trials for patients with IDH1-mutant cancers.

The specific cancers frequently associated with IDH1 mutations include:

• Gliomas: Particularly low-grade gliomas and secondary glioblastomas, where IDH1 mutations are a defining characteristic.
• Acute Myeloid Leukemia (AML): A subset of AML patients exhibit IDH1 mutations, influencing disease prognosis and treatment strategies.
• Cholangiocarcinoma: A rare cancer of the bile ducts, where IDH1 mutations are found in a smaller but significant proportion of cases.
• Chondrosarcoma: Certain types of cartilage tumors also show IDH1 mutations.

Understanding the molecular consequences of IDH1 mutations is critical for developing effective diagnostic tools and targeted treatments, offering hope for improved outcomes in patients with these specific cancer types.